AliveCor announced today that it received FDA clearance for the next generation of its AI technology for the Kardia 12L ECG ...

AliveCor, the global leader in AI-powered cardiology, today announced it has received U.S. Food and Drug Administration (FDA) ...

Atrial fibrillation occurs when action potentials fire very rapidly within the pulmonary veins or atrium in a chaotic manner. The result is a very fast atrial rate — about 400 to 600 beats per minute.

HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through personalized insights, received FDA 510(k) clearance for its 12-lead ECG synthesis software for ...

HeartBeam, Inc. (BEAT) (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, today announced that the U.S. Food and Drug ...

Please provide your email address to receive an email when new articles are posted on . The AMALFI trial evaluated a completely remote approach to atrial fibrillation screening. Remote screening with ...

MADRID — A simple home-based screening strategy that involved wearing an ECG patch for 14 days increased the diagnosis of atrial fibrillation (AF) and associated use of anticoagulants in patients at ...

FDA Clearance Granted After Successful Appeal, Overturning Prior Not Substantially Equivalent (NSE) Outcome HeartBeam’s Credit-Card Sized Device Delivers Clinical-Grade Insights Directly to Patients ...

Madrid, Spain – 29 August 2025: A mail-based atrial fibrillation (AF) screening programme with ECG-patch monitoring led to a modest long-term increase in AF diagnosis and anticoagulation exposure in ...

In the U.S., atrial fibrillation (AF), a heart condition that causes an irregular heartbeat in the upper chambers of the heart, affects up to one in three people in their lifetime. Significant ...